Akums Reveals 12.4% Q4 FY25 Revenue Increase, Maintains FY25 Adjusted EBITDA at 12.3%
Akums Drugs and Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), has announced its financial results for the fourth quarter and fiscal year ending March 31, 2025. The company reported a robust 12.4% year-on-year (YoY) growth in revenue, with Q4 FY25 recording Rs.1,073 crore.
Akums' EBITDA margin stood at 10.4% during Q4, while the company closed FY25 with consolidated total income of Rs. 4,170 crore and an adjusted EBITDA margin of 12.3%. This represents a 7-basis point improvement over the previous year.
One of the significant achievements during the fiscal year was securing an approximately EUR200 million contract for the manufacture and supply of pharmaceutical products to regulated European markets, marking a substantial expansion of Akums' global CDMO footprint. The commercial supplies for this contract will begin in 2027. To support its growing global presence, Akums invested Rs. 272 crore in capital expenditure during FY25.
Akums also maintained a strong focus on research and development (R&D), investing Rs. 130 crore, amounting to over 3% of its revenue. With 973 Drug Controller General of India (DCGI) approvals, the company's product portfolio consists of over 4,000 commercialized formulations across multiple therapeutic areas and 60+ dosage forms.
Segmental Performance Overview
Akums' CDMO business contributed 78% to the group's turnover, with an adjusted EBITDA of 14.1% in FY25. The domestic branded formulation business segment recorded a 9% growth, while the international branded formulation business grew by 14%. The trade generics and API segment continued to operate at a loss, but the company is taking measures to minimize those losses in the coming fiscal year.
Looking ahead, Akums continues to invest in long-term growth drivers, focusing on operational discipline, innovation, and global ambition. The company reported a 16% increase in its R&D spend from FY24, emphasizing quality-focused manufacturing, novel delivery formats, and patient-centric innovations.
Managing Director, Mr. Sanjeev Jain, expressed enthusiasm about Akums' progress, stating, "As we reflect on our first year as a publicly listed company, we look ahead with renewed purpose. Our entry into Europe is a pivotal step in Akums' global CDMO expansion. With strategic capacity expansion and a focus on differentiated offerings, we are laying the foundation for Akums to become a trusted global CDMO, committed to creating long-term value for all stakeholders and delivering healthcare solutions that make a difference across geographies."
Mr. Sandeep Jain, another Managing Director, added, "We are proud to close FY25 on a positive note, especially given the challenges faced in the pharmaceutical industry last year. Despite price erosion in APIs and slowing volumes, we stayed committed to our fundamental principles—operational discipline, innovation, and global ambition. Our new injectable facility is now operational, our R&D engine is stronger than ever, and our differentiated portfolio continues to resonate with partners. These are exciting times as we accelerate our transformation into a global pharmaceutical manufacturing organization."
- Akums Drugs and Pharmaceuticals Ltd., a global player in the pharmaceutical industry, reported a 7-basis point improvement in adjusted EBITDA margin for FY25, signifying progress in their financial health and business growth.
- In the realm of technology and innovation, Akums invested significantly in research and development (R&D), aiming to create quality-focused manufacturing, novel delivery formats, and patient-centric innovations.
- As part of their strategic expansion, Akums secured an approximately EUR200 million contract to manufacture and supply pharmaceutical products to regulated European markets, broadening their global CDMO footprint and delving into new territories of news and technology in the finance sector.
